QRG Capital Management Inc. Grows Stake in GSK plc (NYSE:GSK)

QRG Capital Management Inc. boosted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 20.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 141,414 shares of the pharmaceutical company's stock after purchasing an additional 23,578 shares during the period. QRG Capital Management Inc.'s holdings in GSK were worth $5,241,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. KCS Wealth Advisory increased its stake in shares of GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company's stock valued at $775,000 after purchasing an additional 314 shares in the last quarter. Caprock Group LLC raised its stake in shares of GSK by 2.8% during the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company's stock worth $430,000 after buying an additional 317 shares during the period. Horizon Bancorp Inc. IN lifted its position in shares of GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company's stock valued at $147,000 after buying an additional 323 shares in the last quarter. MONECO Advisors LLC grew its stake in GSK by 2.9% in the 4th quarter. MONECO Advisors LLC now owns 12,433 shares of the pharmaceutical company's stock valued at $461,000 after acquiring an additional 346 shares during the period. Finally, AdvisorNet Financial Inc increased its holdings in GSK by 1.9% in the 4th quarter. AdvisorNet Financial Inc now owns 20,729 shares of the pharmaceutical company's stock worth $768,000 after acquiring an additional 377 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Price Performance

Shares of NYSE:GSK traded up $0.09 during midday trading on Monday, hitting $45.17. The company had a trading volume of 2,830,777 shares, compared to its average volume of 3,484,000. GSK plc has a twelve month low of $33.33 and a twelve month high of $45.41. The stock has a market cap of $93.60 billion, a price-to-earnings ratio of 16.37, a price-to-earnings-growth ratio of 1.93 and a beta of 0.65. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The business's 50-day simple moving average is $42.08 and its 200-day simple moving average is $39.48.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.3762 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.33%. GSK's dividend payout ratio (DPR) is 57.61%.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Guggenheim upgraded shares of GSK from a "neutral" rating to a "buy" rating in a research report on Monday, March 4th. Citigroup upgraded GSK from a "neutral" rating to a "buy" rating in a research note on Tuesday, February 13th. Finally, Morgan Stanley began coverage on GSK in a research report on Tuesday, January 23rd. They issued an "equal weight" rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, GSK presently has an average rating of "Moderate Buy".

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.